|
|
Article: Molecular Insight Pharmaceuticals Augments Research and Development Capability with Key Hire and Appointment of Two New Board Members.
- Article from:
- Business Wire
- Article date:
- June 30, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals announced today that Nicholas Borys, M.D. has joined the company as Chief Medical Officer. Dr. Borys' experience includes extensive work in the development of imaging pharmaceuticals for industry leading companies. The company also reported that Molecular Insight's shareholders have elected two new members to its board of directors. These new directors, Kim D. Lamon M.D., Ph.D., President and Chief Scientific Officer of Valeant Pharmaceuticals International and Harry Stylli, Ph.D., President and Chief Executive Officer of Xencor, Inc. have outstanding track records in researching, developing and commercializing ...
Related newspaper, magazine, and journal articles:
|
|
Article: Molecular Insight Pharmaceuticals, Inc. To ...
Business Wire;
February 6, 2008 ;
700+ words
... ... CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ ... Executive Officer of Molecular Insight Pharmaceuticals, Inc., will present ... Eastern Time Jade Room Molecular Insight Pharmaceuticals, Inc. Company ...
|
|